Skip to main content

Table 1 Patient demographics and baseline characteristics between group A and group B and between group C and group D

From: Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV-related liver failure and liver cirrhosis

Factors

Liver failure

Liver cirrhosis

Group A

Group B

P value

Group C

Group D

P value

Sex (M/F)

34/3

22/5

0.266

26/5

23/5

1.000

Age (years)

40 (35–46.5)

42 (33–50)

0.581

47.5 (37.5–56.5)

44 (35–60)

0.665

ALT (U/L)

88 (46.5–312)

77 (46–336)

0.703

48 (23.25–75.75)

42.5 (25.25–89)

0.716

AST (U/L)

109 (68–173.5)

103 (68–147)

0.760

73 (45.25–131.5)

65 (47.5–92)

0.268

TBIL (mmol/L)

486 (346–550.5)

381 (219–495)

0.053

415 (85.25–488.5)

149 (75.7–306.75)

0.027

PTA

35 (25.5–40.5)

34 (31–47)

0.438

40.5 (29.75–53)

44.5 (34.75–59.25)

0.161

MELD

78 (76.5–81)

77 (75–82)

0.411

76 (73–78)

72 (67.75–76)

0.005

  1. ALT alanine aminotransferase, AST glutamic-oxaloacetic transaminase, TBIL total bilirubin, PTA prothrombin time activity, MELD model for end-stage liver disease